Members log in

Remember me

Do not refresh my screen on timeout

close

News

ABN Clinical Research Fellowship deadline: Sunday 18 November 2018.

Read More

Events

ABN Annual Meeting 2019: 21 - 23 May 2019 - The EICC, Edinburgh

Read More

The Future of Cannabis-based Medicine in UK Healthcare

20 November 2018 - Hallam Conference Centre, London

The Government have responded to renewed pressure to reconsider the statutory framework governing medicinal cannabis. In 2016 the UK Medicines and Healthcare products Regulatory Agency recognised that “products containing Cannabidiol (CBD) used for medical purposes are a medicine.” Following recent high profile public campaigns organised by the parents of childhood epilepsy sufferers, Home Secretary Sajid Javid commissioned a 2018 review into the scheduling of cannabis-based treatments. On the 26th July 2018, the Home Office announced that cannabis-derived medicinal products should be placed in schedule 2 of the Misuse of Drugs Regulation 2001, the effect of which would be to formally acknowledge their therapeutic effects and enable clinicians to prescribe related cannabis-derived medicines.

Although the Home Office has confirmed that it will loosen the rules governing medicinal cannabis, the existing framework and current licensing system for both researchers and patients is highly prohibitive. Before a license may be granted for cannabis-based prescriptions, patients must be able to demonstrate, with the support of a specialist clinician, ‘exceptional clinical circumstances’ to an expert panel (Home Office, 2018). Moreover, the plant will remain an illegal Class B substance under the Misuse of Drugs Act 1971 following the 2018 review. The Government’s 2017 ‘Drug Strategy’ reported cannabis as the most widely recorded illicit drug used by 16-59 year olds. Curbing recreational use has been the Government’s primary policy since 2010.

As the Government is set to amend the prohibition of cannabis for medical purposes, this symposium brings together a range of stakeholders including medical professionals, researchers, central government and healthcare experts, to set out the opportunities and potential risks of cannabis-based treatments for patients. Delegates will inform a coherent strategy for the research and provision of medicinal cannabis in light of the 2018 government review, provide clear insights into potential social and economic implications and identify key areas for public and private sector collaboration.

Key Speakers

Crispin Blunt MP
Co-Chair
APPG on Drug Policy Reform

Professor John Zajicek 
Professor of Medicine
University of St Andrews

Professor Michael Bloomfield 
Honorary Senior Clinical Research Fellow
UCL Clinical Psychopharmacology Unit

Yewande Okuleye 
Research Associate
University of Leicester

Steve Rolles
Senior Policy Director
Transform

Dr Henry Fisher
Partner
Hanway Associates

Delegates Will:

 

For further information please click here

20 November 2018, London

News

ABN Clinical Research Fellowship deadline: Sunday 18 November 2018.

Read More

Events

ABN Annual Meeting 2019: 21 - 23 May 2019 - The EICC, Edinburgh

Read More